Phase 2 Atopic Clinical Trials
46 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 46 trials
Recruiting
Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Atopic Dermatitis
UCB Biopharma SRL160 enrolled68 locationsNCT07277660
Recruiting
Phase 2
Effects of Treatments on Atopic Dermatitis
DermatitisEczemaSkin Diseases+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)130 enrolled1 locationNCT01631617
Recruiting
Phase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled63 locationsNCT07003425
Recruiting
Phase 2
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Jiangsu vcare pharmaceutical technology co., LTD120 enrolled1 locationNCT07598383
Recruiting
Phase 2
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche120 enrolled24 locationsNCT07223697
Recruiting
Phase 2
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Janssen Research & Development, LLC180 enrolled62 locationsNCT07230860
Recruiting
Phase 1Phase 2
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
Atopic Dermatitis
Hangzhou Highlightll Pharmaceutical Co., Ltd156 enrolled1 locationNCT07629778
Recruiting
Phase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Oneness Biotech Co., Ltd.114 enrolled16 locationsNCT06397911
Recruiting
Phase 2
Cardamom and Topical Roseomonas in Atopic Dermatitis
Atopic DermatitisEczema
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT06096857
Recruiting
Phase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled23 locationsNCT07298395
Recruiting
Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting
Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled88 locationsNCT07105488
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
atopic dermatitis (eczema)Atopic DermatitisEczema
Inmagene LLC405 enrolled23 locationsNCT07037901
Recruiting
Phase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Atopic DermatitisEczema, Atopic
Pfizer165 enrolled10 locationsNCT07216027
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled67 locationsNCT07217015
Recruiting
Phase 2
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Atopic DermatitisEczema Atopic DermatitisEczema
Turn Therapeutics110 enrolled1 locationNCT07355075
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled73 locationsNCT06863961
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled98 locationsNCT05995964
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 2
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals84 enrolled28 locationsNCT07220577